Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment of intermediate-2 or high-risk primary or secondary myelofibrosis, a rare disorder of the bone marrow.
A chronic condition, myelofibrosis is characterised by the formation of scar tissue in the bone marrow, disrupting the production of blood cells and leading to severe anaemia and the enlargement of the body’s organs.
